

## Commercial/Healthcare Exchange PA Criteria

Effective: January 1, 2020

**Prior Authorization:** Emsam

**Products Affected:** Emsam (selegiline) topical patch

**Medication Description:** Selegiline is an irreversible MOA-I and at antidepressant doses inhibits both MOA-A and MAO-B. At antidepressant doses, selegiline inhibits both isoenzyme subtypes of MAO (MAO-A and MAO-B); although, a tyramine-modified diet is only necessary if dose is 9 or 12 mg/24 hours. Efficacy was demonstrated in 2 placebo-controlled studies for up to 8 weeks (N=441). In another study (N=322), following an initial response for a mean duration of 25 days, selegiline treatment resulted in significantly longer time to relapse. Periodically reevaluate use for extended duration.

**Covered Uses:** Emsam is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD).

**Exclusion Criteria:**

1. Concomitant use of with selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine, sertraline, and paroxetine); serotonin and norepinephrine reuptake inhibitors (SNRIs, e.g., venlafaxine and duloxetine); the tricyclic antidepressants clomipramine and imipramine, the opiate analgesics meperidine, tramadol, methadone, pentazocine, and propoxyphene; and the antitussive agent dextromethorphan.
2. Concomitant use of carbamazepine
3. Patients with pheochromocytoma

**Required Medical Information:**

1. Diagnosis
2. Past medication trials

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** Prescribed by, or in consultation with, a psychiatrist.

**Coverage Duration:** 12 months

**Other Criteria:**

1. Patient has a document diagnosis of major depressive disorder; AND
2. Patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one of the following antidepressants: bupropion, trazodone, mirtazapine, serotonin norepinephrine reuptake inhibitors (e.g., venlafaxine), selective serotonin reuptake inhibitors (e.g., citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), tricyclic or tetracyclic antidepressants (e.g., amitriptyline, nortriptyline); AND
3. Patient is unable to swallow oral formulations due to oral or motor difficulties, dysphagia, etc.

**References:**

1. Product Information: EMSAM(R) transdermal system, selegiline transdermal system. Mylan Specialty LP (per FDA), Morgantown, WV, 2017.

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	10/15/2019